Following on from information provided to NICE by the company in May 2021, the appraisal of Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1480 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in May 2021, the appraisal of Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2021, the appraisal of Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 19 May 2021 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 08 May 2019 | In progress. Referred 05 December 2016 |
| 11 March 2019 | Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual